ProPhase Labs, Inc. (Formerly Known as Quigley Corporation) to Release Third Quarter Results on Wednesday, November 9th

DOYLESTOWN, PA--(Marketwire - November 02, 2011) -

Highlighted Links

Cold-EEZE

ProPhase Labs

ProPhase Labs (NASDAQ: PRPH) announced today that financial results for the third quarter, ended September 30, 2011, will be released before the market opens on Wednesday, November 9th. A shareholder's conference call will be held later that morning on November 9th, at 11:00am EST. ProPhase Labs Chairman and CEO, Ted Karkus, and COO/CFO Robert Cuddihy will provide a company overview including a review of activities and third quarter results. There will be a question and answer session following initial remarks.

The conference call will be webcast live at:
http://us.meeting-stream.com/prophaselabsinc_110911 at 11:00 AM (EST) on Wednesday, November 9, 2011.

Participants wishing to ask questions may access the live call by dialing (877) 217-6026 conference ID # 21014476. A replay of the conference call will be available for 90 days on the company website www.ProPhaseLabs.com.

About ProPhase Labs

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories LLC ("Phusion"). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. Phusion will formulate and test products to exploit market opportunities within ProPhase's robust OTC distribution channels. For more information visit us at www.ProPhaseLabs.com.